Table 2.
Characteristics of the seven studies included in the meta-analysis
| Study (author, year) | Patient source | Numberof patients | Tumor type | Analysis method | Outcome | HR estimation | NOS score |
|---|---|---|---|---|---|---|---|
| van de Luijtgaarden et al12 2013* | The Netherlands | 44 | Osteosarcoma | IHC | OVS | 0.76 (0.16–3.61)a,b | 7 |
| Wang et al11 2012 | People’s Republic of China | 84 | Osteosarcoma | IHC | OVS | 2.30 (1.66–3.20) | 8 |
| Scotlandi et al15 2011 | Italy | 290 | Ewing sarcoma | IHC | OVS | 0.77 (0.63–0.93)a | 8 |
| van de Luijtgaarden et al16 2013** | The Netherlands | 36 | Ewing sarcoma | IHC | OVS | 1.89 (0.61–5.86)a,b | 7 |
| van Gaal et al19 2013 | The Netherlands | 54 | Rhabdomyosarcoma | IHC | OVS | 18.02 (2.52–128.86)a | 6 |
| Palmerini et al17 2015 | Italy | 88 | Synovial sarcoma | IHC | OVS | 2.50 (1.11–5.63)a | 8 |
| Cheng et al18 2009 | Canada | 31 | Liposarcoma | IHC | OVS | 7.44 (1.59–34.81) | 8 |
Notes:
a
Data extracted from given information.
b
Original data obtained from the author.
*
Osteosarcoma.
**
Ewing’s sarcoma.
Abbreviations: HR, hazard ratio; IHC, immunohistochemistry; NOS, Newcastle–Ottawa Scale; OVS, overall survival.